// App-Quantinova.ai

: Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Researchers

Presenter

  • Cesar Rodriguez

Principal Investigators

  • Katja Weisel

  • Rachid C. Baz

  • Akshanth R. Polepally

  • Jeremy A. Ross

  • Ziyi Jin

  • Kristin D'Amico

  • Orlando F. Bueno

  • Leanne Lash Fleming

  • Peter M. Voorhees

Medical Centers

  • Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest Baptist, Charlotte, NC

  • Medical Oncology and Hematology, Wake Forest University School of Medicine, Winston-Salem, NC

  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL

Locations

  • United States

  • Germany

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Cytokine release syndrome

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Cytokine

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • PF-03084014

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Adaptive

  • Open Label

  • Multicenteric

  • Tolerability

  • Expansion Study

  • Dose Escalation

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved